| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
254,036,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$22.93 - $22.93 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Herendeen Paul |
Exec. V.P. and CFO |
• – – |
2011-03-16 |
4 |
S |
$23.25 |
$9,300,000 |
D/D |
(400,000) |
387,118 |
|
- |
|
| Gilligan Claire A |
Senior V.P. Global Quality |
• – – |
2011-03-16 |
4 |
S |
$23.25 |
$203,996 |
I/I |
(8,774) |
28,561 |
|
- |
|
| Gilligan Claire A |
Senior V.P. Global Quality |
• – – |
2011-03-16 |
4 |
S |
$23.25 |
$410,060 |
D/D |
(17,637) |
53,406 |
|
- |
|
| Bruno Anthony D |
Exec. V.P., Corp. Development |
• – – |
2011-03-16 |
4 |
S |
$23.25 |
$9,300,000 |
D/D |
(400,000) |
324,971 |
|
- |
|
| Connaughton John |
Director |
– • • |
2011-03-10 |
4 |
D |
$0.00 |
$0 |
I/I |
(941,699) |
32,877,566 |
|
- |
|
| Bcip Trust Associates Iii-B |
10% Owner |
– – • |
2011-03-10 |
4 |
D |
$0.00 |
$0 |
I/I |
(941,699) |
32,877,566 |
|
- |
|
| Hara Izumi |
Sr. VP, Gen. Counsel & Sec. |
• – – |
2011-02-17 |
4 |
A |
$0.00 |
$0 |
D/D |
15,680 |
251,693 |
|
- |
|
| Fuhrmann Rochelle |
Senior V.P., Global Finance |
• – – |
2011-02-17 |
4 |
A |
$0.00 |
$0 |
D/D |
15,680 |
27,190 |
|
- |
|
| Gilligan Claire A |
Senior V.P. Global Quality |
• – – |
2011-02-17 |
4 |
A |
$0.00 |
$0 |
D/D |
15,680 |
71,043 |
|
- |
|
| Howard Alvin D |
Sr. V.P., Regulatory Affairs |
• – – |
2011-02-17 |
4 |
A |
$0.00 |
$0 |
D/D |
15,680 |
220,798 |
|
- |
|
| Cross Leland H |
Senior V.P., Tech. Operations |
• – – |
2011-02-17 |
4 |
A |
$0.00 |
$0 |
D/D |
14,110 |
355,599 |
|
- |
|
| Herendeen Paul |
Exec. V.P. and CFO |
• – – |
2011-02-17 |
4 |
A |
$0.00 |
$0 |
D/D |
40,370 |
787,118 |
|
- |
|
| Reichel W Carl |
President, Pharmaceuticals |
• – – |
2011-02-17 |
4 |
A |
$0.00 |
$0 |
D/D |
40,370 |
789,614 |
|
- |
|
| Van Zoonen Marinus Johannes |
Pres., Europe/Intl&Glob. Mkt. |
• – – |
2011-02-17 |
4 |
A |
$0.00 |
$0 |
D/D |
20,490 |
41,617 |
|
- |
|
| Fawzi Mahdi B |
President, Research & Develop. |
• – – |
2011-02-17 |
4 |
A |
$0.00 |
$0 |
D/D |
36,340 |
60,173 |
|
- |
|
| Bruno Anthony D |
Exec. V.P., Corp. Development |
• – – |
2011-02-17 |
4 |
A |
$0.00 |
$0 |
D/D |
40,370 |
724,971 |
|
- |
|
| Ellman Herman |
Senior V.P., Clinical Devel. |
• – – |
2011-02-17 |
4 |
A |
$0.00 |
$0 |
D/D |
14,110 |
241,263 |
|
- |
|
| Boissonneault Roger M |
CEO & President |
• • – |
2011-02-17 |
4 |
A |
$0.00 |
$0 |
D/D |
117,570 |
2,117,632 |
|
- |
|
| Van Zoonen Marinus Johannes |
Pres., Europe/Intl&Glob. Mkt. |
• – – |
2011-01-31 |
4 |
S |
$23.35 |
$51,719 |
D/D |
(2,215) |
21,127 |
|
- |
|
| Howard Alvin D |
Sr. V.P., Regulatory Affairs |
• – – |
2011-01-31 |
4 |
S |
$23.35 |
$13,356 |
D/D |
(572) |
205,118 |
|
- |
|
| Ellman Herman |
Senior V.P., Clinical Devel. |
• – – |
2011-01-31 |
4 |
S |
$23.35 |
$13,356 |
D/D |
(572) |
227,153 |
|
- |
|
| Herendeen Paul |
Exec. V.P. and CFO |
• – – |
2011-01-31 |
4 |
S |
$23.35 |
$50,248 |
D/D |
(2,152) |
746,748 |
|
- |
|
| Cross Leland H |
Senior V.P., Tech. Operations |
• – – |
2011-01-31 |
4 |
S |
$23.35 |
$13,356 |
D/D |
(572) |
341,489 |
|
- |
|
| Gilligan Claire A |
Senior V.P. Global Quality |
• – – |
2011-01-31 |
4 |
S |
$23.35 |
$11,068 |
D/D |
(474) |
55,363 |
|
- |
|
| Fuhrmann Rochelle |
Senior V.P., Global Finance |
• – – |
2011-01-31 |
4 |
S |
$23.35 |
$6,491 |
D/D |
(278) |
11,510 |
|
- |
|
380 Records found
|
|
Page 9 of 16 |
|
|
